Department of Medical Microbiology, Istanbul Medicine Faculty, Istanbul University, 34093 Istanbul, Turkey.
Institute of Health Sciences, Istanbul University, 34126 Istanbul, Turkey.
Viruses. 2024 Sep 3;16(9):1409. doi: 10.3390/v16091409.
Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated ( = 60) and Vaccinated + Previously Infected ( = 60). A commercial sVNT, the ACE2-RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups ( < 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.
中和抗体通过阻止严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）进入细胞，在保护性免疫中发挥主要作用。因此，对抗病毒免疫的特征分析对于预防 SARS-CoV-2 至关重要。在这项研究中，使用基于化学发光微粒子免疫分析（CMIA）的 SARS-CoV-2 IgG II Quant（雅培，Waukegan，IL，美国）检测，对 SARS-CoV-2 感染和/或接种个体中抗 SARS-CoV-2 S1 蛋白 IgG 的中和效果进行了研究，使用替代病毒中和试验（sVNT）。共有 120 名血清阳性个体纳入本研究。他们分为两组：接种组（=60）和接种+既往感染组（=60）。使用商业 sVNT，即 ACE2-RBD 中和试验（Dia.Pro，米兰，意大利）来评估中和效果。该检测分两步进行：筛选和滴定。筛选显示所有血清阳性样本均呈阳性结果。接种组中有 1.7%的低滴度，5%的中滴度，93.3%的高滴度，而另一组中有 1.7%的中滴度和 98.3%的高滴度。ACE2-RBD 滴定试验得出。对于两组，在 1/32 滴定度水平，SARS-CoV-2 IgG II Quant 检测与 ACE2-RBD 滴定检测之间均存在强烈的正相关和显著相关性（均<0.001）。本研究表明，使用 CMIA 方法在 SARS-CoV-2 感染和/或接种后检测到的 SARS-CoV-2 IgG，通过 sVNT 具有很高的中和滴度。这些数据表明，CMIA 确定的血清阳性也表明具有很强的中和作用，这有助于全国范围内的人群保护计划。
